Outlook Therapeutics files to sell 21.72M shares of common stock for holders [Seeking Alpha]
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration [Yahoo! Finance]
Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target lowered by analysts at Ascendiant Capital Markets from $33.00 to $24.00. They now have a "buy" rating on the stock.
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference